Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support research into immunotherapy treatments for (a) pancreatic, (b) brain and (c) other difficult-to-treat cancers; and whether he plans to provide additional funding to clinical trials in this area.

The Department invests in research through its research delivery arm, the National Institute for Health and Care Research (NIHR). The NIHR continues to welcome high quality, high impact funding applications for research into any aspect of human health and care, including research into immunotherapy treatments.

The Department is committed to ensuring that all patients, including those with pancreatic, brain, and other difficult-to-treat cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Department is committed to turbocharging clinical research and delivering better patient care, to make the United Kingdom a world-leading destination for clinical research. We are working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including treatments for cancer.

The Office for Life Sciences’ Cancer Healthcare Goals programme and the Medical Research Council have co-funded and awarded a £9 million grant to the MANIFEST immunotherapy platform. The MANIFEST consortium is led by the Francis Crick Institute and is composed of academia, the National Health Service, and industry partners, with the aim of expanding and advancing UK immunotherapy research and development capabilities, supporting better targeting and improved efficacy of these expensive treatments, and will look to onboard new cancer types and indications as activity progresses.